Top Suppliers:I want be here
Related CAS#:
1428185-57-2 174906-29-7
14510-17-9 158978-31-5
1567972-38-6 862367-68-8
1485012-11-0 1054479-09-2
1480716-90-2 1567866-17-4

64790-15-4

64790-15-4 structure
64790-15-4 structure
  • Name: Glucagon (19-29) (human, rat, porcine) trifluoroacetate salt
  • Chemical Name: h-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr-oh
  • CAS Number: 64790-15-4
  • Molecular Formula: C61H89N15O18S
  • Molecular Weight: 1352.51000
  • Catalog: Peptides
  • Create Date: 2018-10-19 22:06:14
  • Modify Date: 2025-08-25 20:50:20
  • Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
Name h-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr-oh
Synonyms Miniglucagon (huMan,rat,porcine)
Glucagon (19-29) (human,rat,porcine)
GLUCAGON (19-29),HUMAN
AQDFVQWLMNT
glucagon(19-29
Glucagon (19-29) (huMan,rat,porcine) Miniglucagon (huMan,rat,porcine)
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR
GLUCAGON (19-29),BOVINE,HUMAN,PORCINE
GLUCAGON (19-29) (HUMAN,BOVINE,PORCINE)
Glucagon (19-29), human
Description Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
Related Catalog
Target

Insulin secretion[1]

In Vitro Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29)[3].
In Vivo Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein[2].
Animal Admin Rats[1] To test the effect of miniglucagon (Glucagon (19-29)) on stimulated insulin secretion, 8.3 mM glucose is perfused during the experiments, including a 45-min equilibration period, followed by miniglucagon (1, 10, 100, and 1,000 pM) perfused with or without 1 nM tGLP-1. To study the glucagon and miniglucagon secretion, the glucose concentration is switched from 11 to 3 mM after a 45-min stabilization period, and the peptides secreted are measured by radioimmunoassay[1].
References

[1]. Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76.

[2]. Dalle S, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12.

[3]. Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9.
Density 1.339 g/cm3
Boiling Point 1828.5ºC at 760 mmHg
Molecular Formula C61H89N15O18S
Molecular Weight 1352.51000
Flash Point 1059.6ºC
Exact Mass 1351.62000
PSA 582.21000
LogP 2.66020
Index of Refraction 1.596
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:64790-15-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 64790-15-4 | Chemsrc address: https://m.chemsrc.com/en/baike/337477.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved